MedTrace Logo

Anticoagulation and Activation - Comparison in Continuous Renal Replacement Therapy

NCT01276392 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2015-08-20

No results posted yet for this study

Summary

Actual clinical practice predominantly makes use of heparin (systemically) or citrate regionally as anticoagulation in the extracorporeal circulation for renal replacement therapy. We aim to find out if different anticoagulation strategies may lead to different levels of platelet activation and whole blood coagulation. Regarding coagulation activation, it remains uncertain if there is an advantage for one of these methods. However, it is of major interest to minimize the risk of any additional clotting activation via extracorporeal circulation in these usually critically ill patients.

Conditions

  • Kidney Replacement Disorder

Sponsors & Collaborators

  • Klinik für Anästhesiologie

    lead OTHER

Principal Investigators

  • Detlev Kindgen-Milles, Professor,MD · Department of Anesthesiology, University Hospital Duesseldorf, Heinrich Heine University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2014-11-30
Completion
2015-02-28

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01276392 on ClinicalTrials.gov